Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
The first baby from a frozen embryo turns 40!
By Karen Loudon / May 2, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of...
Read More
Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)
By Karen Loudon / April 26, 2024
Ian Nisbet, PhD Chief Operating Officer, Cartherics Pty Ltd As published in pharmaphorum Background The recent acquisition of ImmunoGen by...
Read More
Cartherics enters into Collaborative Research Agreement with TiCARos
By Karen Loudon / April 2, 2024
Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the...
Read More
